Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Targeted Therapies Could Make Rx Companies More Credible, Lilly Exec Says

Executive Summary

A move to more targeted therapies could improve trust of the pharmaceutical industry, Lilly New Product Planning Director Maureen Kiley told a Cambridge Healthtech Institute conference on targeted therapeutics

You may also be interested in...



Rituxan, Herceptin, Gleevec pricing (correction)

The wholesale acquisition cost of Genetech's Rituxan is $13,041 for a one-month course as monotherapy for relapsed/refractory, low grade or follicular, CD20+, B-cell non-Hodgkin's lymphoma and $19,561 for diffuse large CD20+ B-cell NHL (4.2 month average course of treatment); the firm's Herceptin has a WAC of $22,521 for metastatic breast cancer (7.2 month average course at $3,042 per month). According to data from Price Alert, the average wholesale price for Novartis' Gleevec ranges from approximately $3,348.27 to $5,022.36 per month for adults. "The Pink Sheet" reported a discussion of the pricing of the targeted oncologics that was based on inaccurate figures (1"The Pink Sheet" June 26, 2006, p. 22)...

Rituxan, Herceptin, Gleevec pricing (correction)

The wholesale acquisition cost of Genetech's Rituxan is $13,041 for a one-month course as monotherapy for relapsed/refractory, low grade or follicular, CD20+, B-cell non-Hodgkin's lymphoma and $19,561 for diffuse large CD20+ B-cell NHL (4.2 month average course of treatment); the firm's Herceptin has a WAC of $22,521 for metastatic breast cancer (7.2 month average course at $3,042 per month). According to data from Price Alert, the average wholesale price for Novartis' Gleevec ranges from approximately $3,348.27 to $5,022.36 per month for adults. "The Pink Sheet" reported a discussion of the pricing of the targeted oncologics that was based on inaccurate figures (1"The Pink Sheet" June 26, 2006, p. 22)...

FDA’s Rx/Dx Co-Development Approach Overlooks Incentives – Novartis Exec

FDA's concept paper on drug-diagnostic co-development does not account for "practical" issues facing firms, such as incentives, Novartis Oncology Diagnostic Development Director Mark Braganza said

Latest News
See All
UsernamePublicRestriction

Register

PS047329

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel